vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 45.45 percent increase over losses of $(0.11) per share from the same period last year. The company reported $9.00 thousand in sales this quarter. This is the same as the same period last year.
TD Securities Downgrades Shawcor to Hold, Raises Price Target to C$13
TD Securities analyst Aaron Macneil downgrades Shawcor (TSX:SCL) from Buy to Hold and raises the price target from C$12 to C$13.
